Zynerba Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 8.02 million compared to USD 8.82 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.22 a year ago.
Zynerba Pharmaceuticals, Inc.
Equities
ZYNE
US98986X1090
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |